Lec 29(?) (ChatGPT)

tumor micro-environment

How does the composition of the tumor microenvironment (TME) differ between tumors? How does this heterogeneity affect biopsy-based diagnostics and treatment strategies?

Each tumor has a unique TME due to variations in genetic mutations, stromal composition, immune cell infiltration, and extracellular matrix (ECM) density. This heterogeneity complicates biopsies, as a sample from one region may not represent the entire tumor. It also impacts treatment, as different areas may respond differently to therapy, contributing to therapeutic resistance.

How did Virchow’s observations in 1858 contribute to the understanding of cancer development? How does chronic inflammation facilitate tumor progression?

Virchow noted that tumors often develop at sites of chronic irritation, suggesting a link between inflammation and cancer. Chronic inflammation leads to sustained cell proliferation, increased reactive oxygen species (ROS), and secretion of cytokines that promote angiogenesis and immune suppression, all of which contribute to tumor growth and metastasis.

How does the tumor stroma contribute to drug resistance?

The stroma acts as a physical and biochemical barrier, limiting drug penetration and sequestering growth factors that promote tumor survival. Additionally, fibroblasts and immune cells can secrete pro-survival signals

What are some strategies being developed to overcome stromal-mediated resistance?

Strategies to overcome this include stromal-targeting drugs, nanocarrier drug delivery, and combination therapies that modulate the TME.

Why is angiogenesis considered a hallmark of cancer? How does tumor-induced angiogenesis differ from normal vasculature?

Angiogenesis supplies oxygen and nutrients, allowing tumors to grow beyond a critical size. However, tumor blood vessels are often disorganized, leaky, and functionally abnormal, leading to hypoxic regions that promote metastasis and therapeutic resistance.

How does hypoxia activate HIF-1α, and what downstream effects does this activation have on tumor angiogenesis?

Under low oxygen conditions, HIF-1α stabilizes and activates transcription of VEGF, which promotes endothelial cell migration and new blood vessel formation. This angiogenic switch allows tumors to continue growing despite their increasing metabolic demands.

Describe the function of VEGF in tumor angiogenesis. Why do tumors rely on VEGF, and what happens when VEGF signaling is inhibited?

VEGF binds to VEGFR on endothelial cells, initiating proliferation, migration, and vessel formation. Tumors rely on VEGF to create new vasculature, but VEGF inhibition can transiently normalize vessels before tumors adapt through alternative angiogenic pathways.

What role do Matrix Metalloproteinases (MMPs) play in tumor progression? How do they contribute to both angiogenesis and metastasis?

MMPs degrade ECM components, facilitating endothelial migration during angiogenesis. They also break down basement membranes, enabling tumor cells to invade surrounding tissues and enter circulation, promoting metastasis.

What function do pericytes serve in normal vasculature, and why is their detachment significant in tumor angiogenesis?

Pericytes stabilize blood vessels and regulate permeability. In tumors, their detachment weakens vessel integrity, increasing leakiness, interstitial pressure, and inefficient blood flow, contributing to therapy resistance.

How does the abnormal structure of tumor blood vessels contribute to therapeutic resistance? What are potential ways to normalize tumor vasculature?

Leaky and chaotic tumor vessels lead to uneven drug distribution and hypoxic regions, which drive resistance to radiation and chemotherapy. Normalization strategies include low-dose anti-angiogenic therapy to improve perfusion and oxygenation.

How do lymphatic vessels contribute to cancer metastasis? What are potential therapeutic targets within the lymphatic system?

Lymphatic vessels serve as pathways for tumor cells to disseminate to lymph nodes and distant organs. Targeting VEGF-C/VEGFR-3 signaling, which regulates lymphangiogenesis, is a potential approach to limit lymphatic metastasis.

What roles do tumor-associated fibroblasts play in cancer progression? How might targeting TAFs improve treatment outcomes?

TAFs secrete ECM components, growth factors, and cytokines that promote tumor growth, immune evasion, and drug resistance. Targeting their activation or secreted factors (e.g., TGF-β inhibitors) may enhance therapy efficacy.

How does the immune system interact with the tumor microenvironment? Why do some tumors become immunosuppressive, and how can this be therapeutically targeted?

Tumors evade immune detection by recruiting immunosuppressive cells (Tregs, MDSCs) and expressing checkpoint molecules (PD-L1). Checkpoint inhibitors (e.g., anti-PD-1 therapy) restore immune function, enabling tumor clearance.

What role does hyaluronic acid play in the TME, and why does its accumulation increase interstitial fluid pressure? How does this impact drug delivery?

Hyaluronic acid retains water, leading to elevated interstitial pressure that collapses blood vessels and hinders drug penetration. Enzymatic degradation (e.g., hyaluronidase treatment) can enhance drug delivery.

Why have anti-angiogenic therapies had limited long-term success in cancer treatment? What compensatory mechanisms do tumors employ to circumvent these therapies?

Tumors can activate alternative angiogenic pathways (e.g., FGF signaling) or adopt vessel co-option strategies. Combining anti-angiogenics with other therapies may improve long-term efficacy.

How does the unique composition of the TME in different tumors support the need for personalized medicine? What challenges does this pose for standardized cancer treatments?

Different TMEs influence drug response and resistance, necessitating personalized approaches based on TME profiling. However, this heterogeneity complicates treatment standardization and requires individualized therapeutic strategies.